Page last updated: 2024-10-26

ethosuximide and Depressive Disorder, Major

ethosuximide has been researched along with Depressive Disorder, Major in 1 studies

Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.

Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Zhang, K1
Jia, G1
Xia, L1
Du, J1
Gai, G1
Wang, Z1
Cao, L1
Zhang, F1
Tao, R1
Liu, H1
Hashimoto, K1
Wang, G1

Trials

1 trial available for ethosuximide and Depressive Disorder, Major

ArticleYear
Efficacy of anticonvulsant ethosuximide for major depressive disorder: a randomized, placebo-control clinical trial.
    European archives of psychiatry and clinical neuroscience, 2021, Volume: 271, Issue:3

    Topics: Adult; Anticonvulsants; Anxiety; Depressive Disorder, Major; Double-Blind Method; Ethosuximide; Fema

2021